Autor: "Cedarbaum JM" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Seeing with new eyes: finding a path to early intervention trials in Alzheimer's disease.
Autorzy:: Cedarbaum JM
Crans G
Grundman M; Pokaż więcej
Źródło:: Journal of Nutrition, Health & Aging; Apr2010, Vol. 14 Issue 4, p306-309, 4p

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 2.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 5.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 6.

Tytuł:: The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease.
Autorzy:: DeBroff J; Sackler School of Medicine Tel-Aviv University.
Omer N; Sackler School of Medicine Tel-Aviv University.; Movement Disorders Unit Neurological Institute, Tel-Aviv Medical Center.; Laboratory of Early Markers of Neurodegeneration Neurological Institute, Tel-Aviv Medical Center.
Cohen B; Laboratory of Early Markers of Neurodegeneration Neurological Institute, Tel-Aviv Medical Center.
Giladi N; Sackler School of Medicine Tel-Aviv University.; Movement Disorders Unit Neurological Institute, Tel-Aviv Medical Center.; Sagol School of Neuroscience Tel-Aviv University.
Kestenbaum M; Sackler School of Medicine Tel-Aviv University.; Neurology department Meir Hospital Kfar-Saba Israel.
Shirvan JC; Biogen Inc. Cambridge MA USA.
Cedarbaum JM; Biogen Inc. Cambridge MA USA.; Coeruleus Clinical Sciences LLC Woodbridge CT USA.
Gana-Weisz M; Genomic Research Laboratory for Neurodegeneration Tel-Aviv Medical Center Tel-Aviv Israel.
Goldstein O; Genomic Research Laboratory for Neurodegeneration Tel-Aviv Medical Center Tel-Aviv Israel.
Orr-Urtreger A; Sackler School of Medicine Tel-Aviv University.; Sagol School of Neuroscience Tel-Aviv University.; Genomic Research Laboratory for Neurodegeneration Tel-Aviv Medical Center Tel-Aviv Israel.
Mirelman A; Sackler School of Medicine Tel-Aviv University.; Laboratory of Early Markers of Neurodegeneration Neurological Institute, Tel-Aviv Medical Center.; Sagol School of Neuroscience Tel-Aviv University.
Thaler A; Sackler School of Medicine Tel-Aviv University.; Movement Disorders Unit Neurological Institute, Tel-Aviv Medical Center.; Laboratory of Early Markers of Neurodegeneration Neurological Institute, Tel-Aviv Medical Center.; Sagol School of Neuroscience Tel-Aviv University.; Pokaż więcej
Źródło:: Movement disorders clinical practice [Mov Disord Clin Pract] 2023 Mar 21; Vol. 10 (4), pp. 606-616. Date of Electronic Publication: 2023 Mar 21 (Print Publication: 2023).
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Application of longitudinal item response theory models to modeling Parkinson's disease progression.
Autorzy:: Zou H; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Aggarwal V; Critical Path Institute, Tucson, Arizona, USA.
Stebbins GT; Rush University Medical Center, Chicago, Illinois, USA.
Müller MLTM; Critical Path Institute, Tucson, Arizona, USA.
Cedarbaum JM; Coeruleus Clinical Sciences LLC, Woodbridge, Connecticut, USA.
Pedata A; Critical Path Institute, Tucson, Arizona, USA.
Stephenson D; Critical Path Institute, Tucson, Arizona, USA.
Simuni T; Northwestern University Medical Center, Chicago, Illinois, USA.
Luo S; Duke University, Durham, North Carolina, USA.; Pokaż więcej
Źródło:: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2022 Oct; Vol. 11 (10), pp. 1382-1392. Date of Electronic Publication: 2022 Aug 09.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Parkinson Disease*
Disease Progression ; Humans ; Mental Status and Dementia Tests ; Severity of Illness Index

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson's Disease?
Autorzy:: Tosin MHS; Department of Nursing, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil.; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Simuni T; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Stebbins GT; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Cedarbaum JM; Coeruleus Clinical Sciences LLC, Woodbridge, CT, USA.; Department of Neurology, Yale University School of Medicine, New Haven, CT, USA.; Pokaż więcej
Źródło:: Journal of Parkinson's disease [J Parkinsons Dis] 2022; Vol. 12 (4), pp. 1345-1351.
Typ publikacji:: Journal Article
MeSH Terms:: Parkinson Disease*/diagnosis
Parkinson Disease*/drug therapy
Disease Progression ; Humans ; Outcome Assessment, Health Care ; Severity of Illness Index

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial.
Autorzy:: Hutchison RM; Biogen, 300 Binney Street, Cambridge, MA, 02142, USA. .
Evans KC; Biogen, 300 Binney Street, Cambridge, MA, 02142, USA.
Fox T; Biogen, Maidenhead, UK.
Yang M; Biogen, 300 Binney Street, Cambridge, MA, 02142, USA.
Barakos J; Bioclinica, Princeton, NJ, USA.
Bedell BJ; Biospective Inc., Montreal, QC, Canada.
Cedarbaum JM; Coeruleus Clinical Sciences LLC, Woodbridge, CT, USA.
Brys M; Eli Lilly and Company, Indianapolis, IN, USA.
Siderowf A; University of Pennsylvania, Philadelphia, PA, USA.
Lang AE; Morton and Gloria Shulman Movement Disorders Clinic, Toronto, ON, Canada.; Edmond J. Safra Program in Parkinson's Disease, Toronto, ON, Canada.; Pokaż więcej
Źródło:: BMC neurology [BMC Neurol] 2021 Nov 23; Vol. 21 (1), pp. 459. Date of Electronic Publication: 2021 Nov 23.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms:: Dopamine Plasma Membrane Transport Proteins*
Parkinson Disease*/diagnostic imaging
Biomarkers ; Dopamine ; Humans ; Tomography, Emission-Computed, Single-Photon

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers.
Autorzy:: Thaler A; Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.; Laboratory of Early Markers of Neurodegeneration, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Omer N; Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Laboratory of Early Markers of Neurodegeneration, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Giladi N; Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.
Gurevich T; Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.
Bar-Shira A; Genetic Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Gana-Weisz M; Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Goldstein O; Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Kestenbaum M; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Neurology Department, Meir Hospital, Kfar-Saba, Israel.
Shirvan JC; Biogen Inc, Cambridge, MA, USA.
Cedarbaum JM; Biogen Inc, Cambridge, MA, USA.; Coeruleus Clinical Sciences LLC, Woodbridge, CT, USA.
Orr-Urtreger A; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.; Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Regev K; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Neuroimmunology Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Shenhar-Tsarfaty S; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Department of Internal Medicine 'C', 'D', and 'E', Tel-Aviv Medical Center, Tel-Aviv, Israel.
Mirelman A; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.; Laboratory of Early Markers of Neurodegeneration, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.; Pokaż więcej
Źródło:: Journal of Parkinson's disease [J Parkinsons Dis] 2021; Vol. 11 (3), pp. 1285-1296.
Typ publikacji:: Journal Article
MeSH Terms:: Glucosylceramidase*/genetics
Inflammation*/genetics
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2*/genetics
Parkinson Disease*/genetics
Parkinson Disease*/pathology
Biomarkers/analysis ; Cytokines/analysis ; Humans ; Mutation/genetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease.
Autorzy:: Thaler A; Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel. .; Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel. .; Sagol School of Neuroscience, Tel-Aviv University, Tel Aviv-Yafo, Israel. .
Shenhar-Tsarfaty S; Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.; Department of Internal Medicine 'C', 'D', and 'E', Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel.
Shaked Y; Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.
Gurevich T; Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.; Sagol School of Neuroscience, Tel-Aviv University, Tel Aviv-Yafo, Israel.
Omer N; Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.
Bar-Shira A; Genetic Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel.
Gana-Weisz M; Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel.
Goldstein O; Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel.
Kestenbaum M; Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.; Neurology department, Meir Hospital, Kfar-Saba, Israel.
Cedarbaum JM; Biogen Inc, Cambridge, MA, USA.; Coeruleus Clinical Sciences LLC, Woodbridge, CT, USA.
Orr-Urtreger A; Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.; Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel.
Giladi N; Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.; Sagol School of Neuroscience, Tel-Aviv University, Tel Aviv-Yafo, Israel.
Mirelman A; Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.; Sagol School of Neuroscience, Tel-Aviv University, Tel Aviv-Yafo, Israel.; Laboratory of Early Markers of Neurodegeneration, Neurological Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2020 Jun 09; Vol. 10 (1), pp. 9329. Date of Electronic Publication: 2020 Jun 09.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Phenotype*
Glucosylceramidase/*metabolism
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/*metabolism
Metabolic Syndrome/*complications
Parkinson Disease/*complications
Parkinson Disease/*metabolism
Aged ; Female ; Glucosylceramidase/genetics ; Humans ; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/genetics ; Male ; Middle Aged ; Mutation ; Parkinson Disease/genetics ; Probability ; Risk

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.
Autorzy:: Merchant KM; Vincere Biosciences, Inc., and Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Cedarbaum JM; Biogen, Cambridge, MA, USA.
Brundin P; Van Andel Research Institute, Center for Neurodegenerative Science, Grand Rapids, MI, USA.
Dave KD; The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Eberling J; The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Espay AJ; UC Gardner Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH, USA.
Hutten SJ; The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Javidnia M; Center for Health and Technology, University of Rochester Medical Center, Rochester, New York, USA.
Luthman J; Eisai, Woodcliff Lake, NJ, USA.
Maetzler W; Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Menalled L; The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Reimer AN; The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Stoessl AJ; Djavad Mowafaghian Centre for Brain Health, Pacific Parkinson's Research Center, University of British Columbia, Vancouver, BC, Canada.
Weiner DM; Pokaż więcej
Corporate Authors:: The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group
Źródło:: Journal of Parkinson's disease [J Parkinsons Dis] 2019; Vol. 9 (1), pp. 31-61.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Biomarkers*
Clinical Trials as Topic*
Disease Models, Animal*
Guidelines as Topic*
Proof of Concept Study*
Translational Research, Biomedical*
Parkinson Disease/*drug therapy
alpha-Synuclein/*drug effects
Animals ; Consensus ; Humans ; Parkinson Disease/diagnosis ; Research Design

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.
Autorzy:: Stephenson D
Hill D
Cedarbaum JM
Tome M
Vamvakas S
Romero K
Conrado DJ
Dexter DT
Seibyl J
Jennings D
Nicholas T
Matthews D
Xie Z
Imam S
Maguire P
Russell D
Gordon MF
Stebbins GT
Somer E
Gallagher J
Roach A
Basseches P
Grosset D
Marek K; Pokaż więcej
Corporate Authors:: Critical Path for Parkinson’s Consortium
Źródło:: Journal of Parkinson's disease [J Parkinsons Dis] 2019; Vol. 9 (4), pp. 825.
Typ publikacji:: Journal Article; Published Erratum

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Item response theory analysis of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised in the Pooled Resource Open-Access ALS Clinical Trials Database.
Autorzy:: Bacci ED; a Evidera , Bethesda , Maryland.
Staniewska D; a Evidera , Bethesda , Maryland.
Coyne KS; a Evidera , Bethesda , Maryland.
Boyer S; b Biogen , Cambridge , Massachusetts.
White LA; b Biogen , Cambridge , Massachusetts.
Zach N; c Prize4Life , Tel Aviv , Israel.
Cedarbaum JM; b Biogen , Cambridge , Massachusetts.; Pokaż więcej
Corporate Authors:: Pooled Resource Open-Access ALS Clinical Trials Consortium
Źródło:: Amyotrophic lateral sclerosis & frontotemporal degeneration [Amyotroph Lateral Scler Frontotemporal Degener] 2016; Vol. 17 (3-4), pp. 157-67. Date of Electronic Publication: 2015 Oct 16.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Clinical Trials as Topic*
Amyotrophic Lateral Sclerosis/*diagnosis
Amyotrophic Lateral Sclerosis/*physiopathology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Databases, Factual/statistics & numerical data ; Female ; Health Resources/statistics & numerical data ; Humans ; Male ; Middle Aged ; Models, Statistical ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis.
Autorzy:: Shefner J; Department of Neurology, Upstate Medical University, Syracuse, NY 13210-2306, USA. />Cedarbaum JM
Cudkowicz ME
Maragakis N
Lee J
Jones D
Watson ML
Mahoney K
Chen M
Saikali K
Mao J
Russell AJ
Hansen RL
Malik F
Wolff AA; Pokaż więcej
Corporate Authors:: Neals/Cytokinetics Study Team
Źródło:: Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases [Amyotroph Lateral Scler] 2012 Sep; Vol. 13 (5), pp. 430-8. Date of Electronic Publication: 2012 May 16.
Typ publikacji:: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:: Amyotrophic Lateral Sclerosis/*drug therapy
Imidazoles/*pharmacology
Muscle, Skeletal/*drug effects
Neuroprotective Agents/*therapeutic use
Pyrazines/*pharmacology
Riluzole/*therapeutic use
Adult ; Aged ; Female ; Hand Strength/physiology ; Humans ; Imidazoles/adverse effects ; Imidazoles/therapeutic use ; Male ; Middle Aged ; Muscle, Skeletal/physiopathology ; Pyrazines/adverse effects ; Pyrazines/therapeutic use ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Cedarbaum JM"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język